hyperlipidemia who cannot tolerate statins and as a stand-alone treatment, respectively.
Data presented on evolocumab will include:
- Randomized Comparison of the Safety, Tolerability, and Efficacy of Long-Term Administration of AMG 145 Versus Standard of Care in 1104 Patients: 52-Week Results from the OSLER Study
CS.03, Clinical Science: Special Reports, Tuesday, Nov. 19, 4:51 - 5:01 p.m. CST (Ballrooms C1 & C2)
- Efficacy and Safety of Long-Term Treatment with AMG 145 Monotherapy
Abstract 12191, Abstract Poster Session, Tuesday, Nov. 19, 3 - 4:30 p.m. CST (Hall F, Core 2, Poster Board: 2010)
- Efficacy and Tolerability of Long-Term Treatment With AMG 145 in Patients With Statin Intolerance
Abstract 12621, Abstract Poster Session, Tuesday, Nov. 19, 3 - 4:30 p.m. CST (Hall F, Core 2, Poster Board: 2009)
Amgen will also host a webcast investor meeting at AHA on Tuesday, Nov. 19, at 7 p.m. CST. Sean E. Harper, M.D., executive vice president of Research and Development at Amgen, along with members of Amgen's clinical development team and clinical investigators, will participate at the investor meeting to discuss data being presented at AHA.
Live audio of the investor meeting will be simultaneously broadcast over the Internet and will be available to members of the news media, investors and the general public.
The webcast of the conference, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the evPage: 1 2 3 4 5 6 7 Related biology technology :1
. Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting2
. Amgen Presents New Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma3
. Amgen And ShanghaiTech University Announce Plans For Amgen China R&D Center To Open On ShanghaiTech Campus4
. Amgen And Servier Complete Product Collaboration Transaction5
. Amgen Announces 2013 Third Quarter Dividend6
. Technical Briefing: Amgen, PDL BioPharma, Questcor Pharma, and BioCryst Pharma7
. Amgen And Servier Announce Product Collaboration8
. Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations9
. Amgen And AstraZeneca Highlight Data To Be Presented At European League Against Rheumatism Annual Meeting10
. Amgen Announces Top-Line Results Of Phase 3 Talimogene Laherparepvec Trial In Melanoma11
. Amgen Announces 2013 Second Quarter Dividend